BDTX Key Statistics, Chart & Performance
The current stock price of BDTX is 2.59 USD. In the past year, price decreased by -1.15%.
BDTX Technical Analysis
BDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BDTX. BDTX has an excellent financial health rating, but there are some minor concerns on its profitability.
BDTX Financial Highlights
Over the last trailing twelve months BDTX reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 127.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.69% | ||
| ROA | 13.62% | ||
| ROE | 17.03% | ||
| Debt/Equity | 0 |
BDTX Forecast & Estimates
15 analysts have analysed BDTX and the average price target is 9.44 USD. This implies a price increase of 264.29% is expected in the next year compared to the current price of 2.59.
BDTX Ownership
About BDTX
Company Profile
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Company Info
BLACK DIAMOND THERAPEUTICS I
245 First Street, 18Th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: David M. Epstein
Employees: 24
Phone: 16174175868
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
Can you describe the business of BLACK DIAMOND THERAPEUTICS I?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
What is the current price of BDTX stock?
The current stock price of BDTX is 2.59 USD. The price increased by 1.17% in the last trading session.
Does BLACK DIAMOND THERAPEUTICS I pay dividends?
BDTX does not pay a dividend.
How is the ChartMill rating for BLACK DIAMOND THERAPEUTICS I?
BDTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is BLACK DIAMOND THERAPEUTICS I (BDTX) stock traded?
BDTX stock is listed on the Nasdaq exchange.
What do analysts say about BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
15 analysts have analysed BDTX and the average price target is 9.44 USD. This implies a price increase of 264.29% is expected in the next year compared to the current price of 2.59.